10:44 AM EDT, 06/27/2024 (MT Newswires) -- X4 Pharmaceuticals ( XFOR ) shares fell 30% in recent Thursday trading even after the company said its phase 2 trial assessing the safety and efficacy of mavorixafor as a treatment for chronic neutropenia yielded "positive interim clinical data".

Interim analysis of the ongoing six-month study indicated once-daily oral mavorixafor was well tolerated and consistently raised participants' absolute neutrophil counts, both alone and in combination with stable doses of injectable granulocyte colony-stimulating factor, X4 Pharmaceuticals ( XFOR ) said Thursday.

The company is screening patients for its global phase 3 trial, evaluating oral mavorixafor's efficacy in treating severe chronic neutropenia.

Intraday trading volume topped 5.8 million shares versus the daily average of 2.7 million.

Price: 0.70, Change: -0.30, Percent Change: -30.40